BriaCell Therapeutics Corp.

What they do

BriaCell is a clinical-stage biotech developing novel immunotherapies, primarily Bria-IMT, a targeted immunotherapy combined with the checkpoint inhibitor retifanlimab for metastatic breast cancer. The company is also developing Bria-OTS (also known as Bria-BRES), a personalized off-the-shelf immunotherapy, and its advanced form Bria-OTS+, for various cancers. Bria-IMT has Fast Track designation from the FDA, and the company is currently advancing a pivotal Phase 3 study (NCT06072612) in metastatic breast cancer.

Revenue drivers

• Bria-IMT combination therapy — Lead product candidate; no revenue yet, potential future sales from approved metastatic breast cancer treatment.
• Bria-OTS / Bria-OTS+ platform — Personalized off-the-shelf immunotherapy platform in development for multiple cancers; no current revenue.
• Bria-PROS+ — Prostate cancer candidate in preclinical development; received positive Pre-IND feedback from FDA; no current revenue.

Recent performance

For fiscal 2025 (year ended July 31, 2025), the company reported a net loss of $26.3 million, compared to a net loss of $4.8 million in fiscal 2024. Diluted EPS was $-62.19 in fiscal 2025, down from $-43.68 in fiscal 2024. Operating cash flow was negative $28.2 million in fiscal 2025, compared to negative $24.1 million in fiscal 2024. As of April 30, 2026, the company had $6.9 million in cash and equivalents, total assets of $27.1 million, and shareholder equity of $23.4 million.

Strategy

BriaCell is focused on advancing its lead candidate Bria-IMT through a pivotal Phase 3 study in metastatic breast cancer, with potential full FDA approval upon positive completion. The company is also developing its Bria-OTS platform for multiple cancer types, including a Phase 1/2 study in metastatic breast cancer (NCT06471673) and a Pre-IND program for Bria-PROS+ in prostate cancer. Recent 8-K filings indicate the company has entered material agreements and engaged in equity sales to fund operations.

Risks

• Clinical trial failure — Pre-clinical and early-stage results may not predict outcomes in larger, diverse populations; many life sciences companies have experienced setbacks in advanced trials.
• Regulatory hurdles — FDA may disagree with data analysis, require additional studies, or delay/deny approval for Bria-IMT or other candidates.
• Cash burn and funding — Operating cash flow has been consistently negative (e.g., -$28.2M in fiscal 2025), and cash of $6.9M may be insufficient to fund all planned activities without additional financing.
• Dependence on partners — Retifanlimab is manufactured by Incyte; reliance on third-party suppliers for combination therapy could impact development.

Outlook

Management is focused on completing the pivotal Phase 3 study of Bria-IMT with retifanlimab in metastatic breast cancer, with the goal of regulatory approval. The company also plans to continue advancing Bria-OTS/Bria-BRES in a Phase 1/2 study and pursue Bria-PROS+ for prostate cancer. Given the current cash position, additional capital raises are likely to be needed to fund ongoing operations and clinical trials.